PDE-5 Dipsticks
On the basis of application, the global pulmonary arterial hypertension market is classified into:
Hospitals
Clinics
Others
ERAs was the largest segment in the current scenario. However, the prostacyclin and
prostacyclin analogs segment is projected to expand at the highest CAGR over the forecast
period, owing to the authorization of Orenitram (treprostinil extended release tablet) in 2013
and the anticipated endorsement of Uptravi (selexipag) in 2016.
Growing prevalence of cardiac diseases to drive growth of the overall pulmonary arterial
hypertension (PAH) market
Owing to the sedentary lifestyles, growing consumption of fast food, and lack of exercise, the
global numbers for the patients with cardiac diseases is expected to rise substantially over the
forecast period thereby, increasing the susceptibility of pulmonary arterial hypertension among
the global population. This would propel the overall growth of the PAH market in the near
future.
North America accounted for the largest market share of the global PAH treatment market,
followed by Europe. These regional market are projected to witness considerable growth in the
forecast period, owing to the freshly approved PAH medicines in the market and high
prevalence of heart diseases.
Browse Complete Report For More Information @
https://www.coherentmarketinsights.com/ongoing-insight/pulmonary-arterial-hypertension-pah-
market-203
Some of the major companies operating in the pulmonary arterial hypertension (PAH) market in
the current scenario are Actelion Pharmaceuticals, Ltd., Gilead Sciences, Inc., United
Therapeutics Corporation, Bayer HealthCare, Pfizer, Inc., Novartis International AG and
GlaxoSmithKline plc.
About Coherent Market Insights
Coherent Market Insights is a prominent market research and consulting firm offering action-
ready syndicated research reports, custom market analysis, consulting services, and competitive